Investigational Compound

What Is GLP3 (Retatrutide)?

The investigational GLP-1, GIP and glucagon triple agonist from Eli Lilly: what it is, what Phase 3 trials reported, and where it stands with the FDA.

Investigational — Not FDA-Approved
25.0%
Mean weight loss, 12 mg, 80 wk · TRIUMPH-1
24.2%
Mean weight loss, 12 mg, 48 wk · Phase 2
Triple
Receptor Agonist
Q1 2027
Planned FDA Filing

Explore the Evidence

Detailed pages on retatrutide's mechanism, trial results, safety data and regulatory status.

What is GLP3?

GLP3 (also written GLP-3) is the informal name for retatrutide (LY3437943), Eli Lilly's investigational once-weekly injectable. It activates three receptors: GLP-1, GIP and glucagon. It is not FDA-approved. In the Phase 3 TRIUMPH-1 trial (NEJM 2026), adults with obesity on the 12 mg dose lost a mean of 25.0% of body weight at 80 weeks, compared with 3.9% on placebo. Lilly plans to submit a Biologics License Application to the FDA in Q1 2027.

NamesRetatrutide, LY3437943; informally GLP3, GLP-3, "Reta"
DeveloperEli Lilly and Company
MechanismTriple agonist of the GLP-1, GIP and glucagon receptors
How it was studiedOnce-weekly subcutaneous injection, with dose escalation
Phase 2 result24.2% mean weight loss at 48 weeks, 12 mg (NEJM 2023)
Phase 3 result25.0% mean weight loss at 80 weeks, 12 mg, vs 3.9% placebo (TRIUMPH-1, NEJM 2026)
Regulatory statusInvestigational. Not FDA-approved. BLA submission planned for Q1 2027

GLP3-R, GLP-3 RT, "Reta" and GLP3-B: what the names mean

"GLP3" is shorthand, not an official drug name. There is no hormone called GLP-3 and no GLP-3 receptor; the nickname places retatrutide one step beyond GLP-1 drugs such as semaglutide and dual GLP-1/GIP drugs such as tirzepatide.

  • GLP3-R, GLP-3 RT, GLP3 RT, R3T, "Reta": labels that research-peptide sellers commonly print on vials meant to contain retatrutide. These are marketing abbreviations, not regulatory names, and the products carrying them are sold as "research use only", not for human use. See the black-market warning for the purity and contamination risks.
  • GLP3-B and similar capsule products: marketed as dietary supplements. They are not retatrutide. Retatrutide has only been studied as a once-weekly injection; no oral form has been tested in published trials, so a capsule sold as "GLP3" is not the molecule studied in the TRIUMPH program. See what GLP3-B is and what its sellers list as ingredients.

How retatrutide works

Retatrutide engages three receptors involved in energy balance and body-weight regulation:

  • GLP-1 receptor: reduces appetite, slows gastric emptying and improves glycemic control. This is the pathway of semaglutide (Ozempic/Wegovy).
  • GIP receptor: enhances insulin secretion and may contribute to fat mobilization. Tirzepatide (Mounjaro/Zepbound) adds this pathway to GLP-1.
  • Glucagon receptor: associated in published studies with increased energy expenditure and hepatic fat oxidation. Semaglutide and tirzepatide, the incretin drugs FDA-approved for weight management, do not act on the glucagon receptor.

For receptor-binding detail, see retatrutide's mechanism of action.

What the clinical trials reported

Every figure below is a group average reported under trial conditions. None is an individual outcome or a result this site offers. Peer-reviewed figures count every randomized participant, including those who stopped treatment (the treatment-regimen, or intention-to-treat, estimand).

TrialPopulationDurationMean weight loss (by dose)
Phase 2 (Jastreboff et al., NEJM 2023)Adults with obesity, or overweight with a weight-related condition48 weeksUp to 24.2% (12 mg)
TRIUMPH-1 (Phase 3, NEJM 2026)Adults with obesity, without diabetes80 weeks17.6% (4 mg), 23.7% (9 mg), 25.0% (12 mg); placebo 3.9%
TRIUMPH-2 (Phase 3, Lancet 2026)Adults with obesity or overweight and type 2 diabetes80 weeks11.9% (4 mg), 16.8% (9 mg), 18.8% (12 mg); placebo 5.1%
TRIUMPH-3 (Phase 3, Lilly topline)Adults with severe obesity and established cardiovascular disease80 weeks21.6% (9 mg), 22.6% (12 mg); placebo 3.2% (participants who stayed on treatment)

Lilly's earlier press releases quoted higher figures for participants who stayed on treatment (the efficacy estimand): 28.3% at 12 mg in TRIUMPH-1 and 20.8% in TRIUMPH-2. TRIUMPH-3 is not yet peer-reviewed, so only Lilly's on-treatment topline is available. The clinical trials page covers each study's design, and the week-by-week trial weight data shows how the averages changed over time.

GLP-1 vs GLP-3: semaglutide, tirzepatide and retatrutide

SemaglutideTirzepatideRetatrutide ("GLP-3")
ReceptorsGLP-1GLP-1 + GIPGLP-1 + GIP + glucagon
Brand namesWegovy, OzempicZepbound, MounjaroNone (investigational)
FDA statusApproved for chronic weight managementApproved for chronic weight managementNot approved; BLA planned Q1 2027
Pivotal weight-loss trial14.9% at 68 weeks, 2.4 mg (STEP 1)20.9% at 72 weeks, 15 mg (SURMOUNT-1)25.0% at 80 weeks, 12 mg (TRIUMPH-1)

All three figures count every randomized participant, but the trials enrolled different populations over different durations, so they are not a head-to-head comparison. See the plain-language GLP-1 vs GLP-3 comparison or the full retatrutide vs semaglutide vs tirzepatide breakdown.

Is GLP3 safe? Reported side effects

Across the TRIUMPH trials, the most common adverse events were gastrointestinal (nausea, diarrhea, constipation and vomiting) and were generally mild to moderate. Dysesthesia, an abnormal skin sensation, was reported in a subset of TRIUMPH-1 participants and was usually mild. In TRIUMPH-1, Lilly reported discontinuation due to adverse events of 4.1% (4 mg), 6.9% (9 mg) and 11.3% (12 mg), vs 4.9% on placebo. In TRIUMPH-3 it was 9.8% (9 mg) and 13.5% (12 mg), vs 4.8%.

Long-term safety has not been established, and the trial safety data applies only to the pharmaceutical-grade compound used in those trials, not to unregulated products sold online. See is GLP3 safe? Side-effect rates from each trial and the contraindications reported for this drug class. Related evidence pages cover how doses were escalated in the trials and what is known about alcohol and retatrutide.

FDA status, availability and cost

Retatrutide is not FDA-approved and has no approved prescription price. Lilly plans to submit its Biologics License Application in Q1 2027; FDA review typically takes months after submission. Until then, the compound is available only to people enrolled in clinical trials. Products sold online as "retatrutide", "GLP3-R" or "GLP-3 RT" are labeled for research use only and are not approved for human use.

For general market pricing of the FDA-approved GLP-1 drugs, see what FDA-approved GLP-1 medications cost.

GLP3 frequently asked questions

Yes. GLP3 (also written GLP-3) is an informal name for retatrutide, Eli Lilly's investigational triple agonist of the GLP-1, GIP and glucagon receptors. Its development code is LY3437943. The names refer to the same molecule.

No. GLP3-B and similar capsule products are marketed as dietary supplements. Retatrutide has only been studied as a once-weekly injection, and no oral form has been tested in published trials.

They are labels research-peptide sellers use for vials meant to contain retatrutide. They are not regulatory names, and products sold under them are labeled for research use only, not for human use.

No. Retatrutide is investigational. Eli Lilly has reported Phase 3 TRIUMPH results and plans to submit a Biologics License Application to the FDA in Q1 2027.

In the Phase 2 trial (NEJM 2023), the 12 mg dose produced a mean weight loss of 24.2% at 48 weeks. In the Phase 3 TRIUMPH-1 trial (NEJM 2026), the 12 mg dose produced a mean of 25.0% at 80 weeks, compared with 3.9% on placebo. These are trial averages, not individual results.

GLP-1 drugs such as semaglutide activate one receptor. Tirzepatide activates two (GLP-1 and GIP). Retatrutide, nicknamed GLP-3, activates three: GLP-1, GIP and glucagon. Semaglutide and tirzepatide are FDA-approved for weight management; retatrutide is not.

Safety has only been studied under clinical-trial supervision. The most common side effects were gastrointestinal. On the 12 mg dose, Lilly reported that 11.3% of TRIUMPH-1 participants and 13.5% of TRIUMPH-3 participants stopped because of adverse events, compared with 4.9% and 4.8% on placebo. Long-term safety is not established, and unregulated online products carry additional purity and contamination risks.

Eli Lilly plans to submit retatrutide to the FDA in Q1 2027. It can only be prescribed after FDA approval, and the review typically takes months after submission. No approval date has been announced.

Sources

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315.
  2. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026. PMID 42814954.
  3. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). Lancet. 2026. PMID 42810372.
  4. Eli Lilly and Company. TRIUMPH-1 topline press release. May 21, 2026.
  5. Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 topline press release (includes the Q1 2027 BLA plan). July 23, 2026.
  6. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID 33567185.
  7. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID 35658024.

Written and maintained by the GLP3 Weight Loss Editorial Team. Last updated October 28, 2026. Educational content only, not medical advice. GLP3 Weight Loss is not a healthcare provider and does not prescribe, dispense or sell retatrutide for human use.

Talk to an Independent Licensed Provider

This site is an independent educational resource. We do not prescribe, dispense, or treat. Any decision about FDA-approved weight-management peptide is between you and your own licensed provider.

Independent Licensed Providers
See My Options →

We refer you to independent third-party licensed providers. We are not a medical practice or pharmacy.